According to the American Heart Association, there are approximately 5.1 million Americans currently living with heart failure. For patients with a more advanced condition of heart failure, Ventricular Assist Devices are sometimes an option. In 2010, more than 1,400 LVAD devices were implanted into patients in the U.S. alone.About Cardiovascular Cell Therapy Research Network (CCTRN) and NHLBI The CCTRN consists of a data coordinating center and seven medical centers in the United States with expertise in stem cell-based clinical trials for cardiovascular diseases. The CCTRN has successfully completed and published the results of three adult stem cell trials to date (TIME, LateTIME, and FOCUS) and is currently executing a study of regenerative cell therapy for peripheral arterial disease called PACE. Further information on CCTRN is available at: cctrn.org. The National Heart, Lung, and Blood Institute (NHLBI) is a component of the National Institutes of Health (NIH). NHLBI plans, conducts, and supports research related to the causes, prevention, diagnosis, and treatment of heart, blood vessel, lung, and blood diseases; and sleep disorders. The Institute also administers national health education campaigns on women and heart disease, healthy weight for children, and other topics. NHLBI press releases and other materials are available at: nhlbi.nih.gov. About Cytori Therapeutics Cytori Therapeutics is developing cell therapies based on autologous adipose-derived regenerative cells (ADRCs™) to treat cardiovascular disease and other medical conditions. Our scientific data suggest ADRCs™ improve blood flow, modulate the inflammatory response and rescue tissue at risk of dying. As a result, we believe these cells can be applied across multiple “ischemic” conditions. These therapies are made available to the physician and patient at the point-of-care by Cytori’s proprietary technologies and products, including the Celution® System product family. www.cytori.com Cautionary Statement Regarding Forward-Looking Statements This communication includes forward-looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position. Such statements including those regarding NHLBI’s intent to enroll 34 patients in the CELLVAD-ADRC trial, are subject to risks and uncertainties that could cause the scope of the trial to change from the approved plan. Some of these risks include clinical and regulatory uncertainties, risks in the collection and results of clinical data, clinical outcomes, dependence on third party performance, and other risks and uncertainties described under the "Risk Factors" in Cytori's Securities and Exchange Commission Filings. We assume no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made.
The Celution® System is available in the United States for investigational use only.